Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Neurology

The Genetics and Biology of AD-HSP

At a Glance

Autosomal Dominant Complex Spastic Paraplegia (AD-HSP) is caused by genetic mutations that disrupt how long nerve cells transport essential materials. This leads to leg stiffness and other neurological symptoms. A mutation in just one copy of the gene is enough to cause the condition.

To understand Autosomal Dominant Complex Spastic Paraplegia, it helps to look inside your body’s cells. Your nerves are like the longest electrical wires in the world, stretching from your brain all the way down to your legs [1]. For these long nerves to stay healthy, they need a constant supply of “supplies” and “fuel” sent from one end to the other [2][3]. In your condition, a genetic change creates a “traffic jam” that slowly causes these long wires to wear down [4][5].

The “Family Blueprint”: Autosomal Dominant Inheritance

Every person has two copies of most genes—one from each parent. Autosomal dominant means that only one of these copies needs to have a mutation (a change in the “blueprint”) to cause the condition [6].

  • 50% Chance: If a parent has the gene change, there is a 50% chance they will pass it on to each child [6].
  • De Novo Mutations: In some cases, a patient may be the first in their family to have the condition because the mutation happened for the first time in them (this is called a de novo mutation) [7].

Common Genetic Subtypes of Complex AD-HSP

Doctors use the letters “SPG” (which stands for Spastic Paraplegia Gene) followed by a number to name the different types of HSP [1]. While many of these usually cause “pure” symptoms, some are frequently “complex,” meaning they affect other parts of the nervous system [8][9].

  • SPG4 (SPAST gene): This is the most common type. While often “pure,” it can sometimes be “complex,” leading to changes in thinking or memory (cognitive impairment) [10][11].
  • SPG10 (KIF5A gene): This type is often complex and may involve peripheral neuropathy (numbness or tingling in the hands/feet). In some families, mutations in this same gene can look like ALS [12][13].
  • SPG17 (BSCL2 gene): Also known as Silver Syndrome, this type often causes wasting of the small muscles in the hands along with leg stiffness [14][15].
  • SPG6 (NIPA1 gene): This can present with complex features like epilepsy or more severe physical involvement [16][17].
  • SPG30 (KIF1A gene): A type that can cause a wide range of “complex” symptoms, including balance issues (ataxia) [18][19].

The Biology: Why Do the Nerves Wear Down?

The mutations in these genes disrupt the “maintenance” system of your nerve cells in three main ways:

  1. Traffic Jams (Microtubule Dysfunction): Genes like SPAST and KIF5A help build and move things along the “highways” (microtubules) inside your nerves [20][5]. When these genes don’t work, the cell can’t deliver vital supplies to the far ends of the nerves in your legs [4][13].
  2. Construction Defects (ER Modeling): The endoplasmic reticulum (ER) is the cell’s factory. Genes like SPAST and REEP1 help shape this factory [21][3]. If the factory is misshapen, it causes ER stress, which eventually damages the cell [22].
  3. Fuel Storage Problems (Lipid Metabolism): Genes like BSCL2 (Seipin) help the cell manage fats (lipids) [23]. If the cell can’t store or use fat correctly, it loses an important source of energy and structural material [24][25].

Because the nerves going to your legs are the longest in your body, they are the most sensitive to these “traffic jams” and “factory defects,” which is why the legs are usually affected first and most severely [1][26].

Common questions in this guide

What does autosomal dominant inheritance mean for AD-HSP?
Autosomal dominant means that a mutation in only one copy of a gene is enough to cause the condition. If a parent carries this mutation, there is a 50 percent chance they will pass it on to each of their children.
Can I have AD-HSP if no one else in my family has it?
Yes, it is possible to be the first person in your family with the condition. This happens when the genetic change occurs for the first time in you, which doctors call a de novo mutation.
What makes AD-HSP 'complex' instead of 'pure'?
While pure forms of HSP mainly affect the legs, complex AD-HSP involves other parts of the nervous system. This can lead to additional symptoms like numbness in the hands and feet, memory issues, epilepsy, or balance problems.
Why does AD-HSP mainly affect my legs?
The condition disrupts how your nerve cells transport essential supplies and fuel. Because the nerves running down to your legs are the longest in your body, they are the most sensitive to these transportation issues and tend to wear down first.
What are the most common genes involved in AD-HSP?
Doctors identify different types of the condition using SPG numbers. Common genes linked to complex symptoms include SPAST (SPG4), KIF5A (SPG10), BSCL2 (SPG17), NIPA1 (SPG6), and KIF1A (SPG30).

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific 'SPG' number, and which gene is involved in my diagnosis?
  2. 2.Based on my specific mutation, are there certain 'complex' symptoms (like vision changes or memory issues) I should be more closely monitored for?
  3. 3.Does my genetic test result suggest a 'loss-of-function' or a 'gain-of-function' mechanism?
  4. 4.Was my mutation likely inherited from a parent, or is it a 'de novo' (new) mutation?
  5. 5.How does this genetic information affect the risk for my children or siblings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Hereditary spastic paraplegia caused by compound heterozygous mutations outside the motor domain of the KIF1A gene.

    Krenn M, Zulehner G, Hotzy C, et al.

    European journal of neurology 2017; (24(5)):741-747 doi:10.1111/ene.13279.

    PMID: 28332297
  2. 2

    Subclinical involvement of central nervous system structures other than motor or sensory tracts in SPG3A and SPG4 patients.

    Sobanska A, Sulek A, Stepniak I, et al.

    BMC neurology 2026; (26(1)):74 doi:10.1186/s12883-025-04624-4.

    PMID: 41507865
  3. 3

    The interconnection of endoplasmic reticulum and microtubule and its implication in Hereditary Spastic Paraplegia.

    Wang X, Fan C, Liu Y, Zou Y

    Computational and structural biotechnology journal 2023; (21()):1670-1677 doi:10.1016/j.csbj.2023.02.025.

    PMID: 36860342
  4. 4

    Functional differences of short and long isoforms of spastin harboring missense mutation.

    Plaud C, Joshi V, Kajevu N, et al.

    Disease models & mechanisms 2018; (11(9)) doi:10.1242/dmm.033704.

    PMID: 30213879
  5. 5

    ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function.

    Baron DM, Fenton AR, Saez-Atienzar S, et al.

    Cell reports 2022; (39(1)):110598 doi:10.1016/j.celrep.2022.110598.

    PMID: 35385738
  6. 6

    Association of an insertion mutation in PRRT2 with hereditary spastic paraplegia accompanied by polyneuropathy.

    Wang Z, Dong H, Ji X, et al.

    Journal of clinical laboratory analysis 2021; (35(6)):e23772 doi:10.1002/jcla.23772.

    PMID: 33826176
  7. 7

    Clinical and Genetic Features of Chinese Patients With NIPA1-Related Hereditary Spastic Paraplegia Type 6.

    Fu J, Ma M, Li G, Zhang J

    Frontiers in genetics 2022; (13()):859688 doi:10.3389/fgene.2022.859688.

    PMID: 35464835
  8. 8

    Triple A syndrome presenting as complicated hereditary spastic paraplegia.

    Leveille E, Gonorazky HD, Rioux MF, et al.

    Molecular genetics & genomic medicine 2018; (6(6)):1134-1139 doi:10.1002/mgg3.492.

    PMID: 30381913
  9. 9

    Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia.

    Sáenz-Farret M, Lang AE, Kalia L, et al.

    Movement disorders clinical practice 2022; (9(4)):522-529 doi:10.1002/mdc3.13437.

    PMID: 35586535
  10. 10

    Comprehensive Characterization of Spastic Paraplegia in Korean Patients: A Single-Center Experience over Two Decades.

    Choi Y, Kim SH, Ahn SJ, et al.

    Yonsei medical journal 2026; (67(1)):34-41 doi:10.3349/ymj.2024.0500.

    PMID: 41431411
  11. 11

    Cortical Damage Associated With Cognitive and Motor Impairment in Hereditary Spastic Paraplegia: Evidence of a Novel SPAST Mutation.

    Lin JZ, Zheng HH, Ma QL, et al.

    Frontiers in neurology 2020; (11()):399 doi:10.3389/fneur.2020.00399.

    PMID: 32536902
  12. 12

    KIF5A-dependent axonal transport deficiency disrupts autophagic flux in trimethyltin chloride-induced neurotoxicity.

    Liu M, Pi H, Xi Y, et al.

    Autophagy 2021; (17(4)):903-924 doi:10.1080/15548627.2020.1739444.

    PMID: 32160081
  13. 13

    KIF5A regulates axonal repair and time-dependent axonal transport of SFPQ granules and mitochondria in human motor neurons.

    Guerra San Juan I, Brunner JW, Eggan K, et al.

    Neurobiology of disease 2025; (204()):106759 doi:10.1016/j.nbd.2024.106759.

    PMID: 39644980
  14. 14

    Role of Seipin in Human Diseases and Experimental Animal Models.

    Li Y, Yang X, Peng L, et al.

    Biomolecules 2022; (12(6)) doi:10.3390/biom12060840.

    PMID: 35740965
  15. 15

    Clinical features of inherited neuropathy with BSCL2 mutations in Japan.

    Ishihara S, Okamoto Y, Tanabe H, et al.

    Journal of the peripheral nervous system : JPNS 2020; (25(2)):125-131 doi:10.1111/jns.12369.

    PMID: 32108980
  16. 16

    Is NIPA1-associated hereditary spastic paraplegia always 'pure'? Further evidence of motor neurone disease and epilepsy as rare manifestations.

    Tanti M, Cairns D, Mirza N, et al.

    Neurogenetics 2020; (21(4)):305-308 doi:10.1007/s10048-020-00619-0.

    PMID: 32500351
  17. 17

    Clinical and genetic characterization of NIPA1 mutations in a Taiwanese cohort with hereditary spastic paraplegia.

    Fang SY, Chou YT, Hsu KC, et al.

    Annals of clinical and translational neurology 2023; (10(3)):353-362 doi:10.1002/acn3.51724.

    PMID: 36607129
  18. 18

    A Japanese Family with a Novel Pathogenic Variant in KIF1A Presenting with Spastic Paraparesis, Cerebellar Ataxia, and Intellectual Disability.

    Mitsutake A, Kawai M, Orimo K, et al.

    Cerebellum (London, England) 2024; (24(1)):20 doi:10.1007/s12311-024-01782-y.

    PMID: 39730866
  19. 19

    KIF1A variants are a frequent cause of autosomal dominant hereditary spastic paraplegia.

    Pennings M, Schouten MI, van Gaalen J, et al.

    European journal of human genetics : EJHG 2020; (28(1)):40-49 doi:10.1038/s41431-019-0497-z.

    PMID: 31488895
  20. 20

    Structure of spastin bound to a glutamate-rich peptide implies a hand-over-hand mechanism of substrate translocation.

    Han H, Schubert HL, McCullough J, et al.

    The Journal of biological chemistry 2020; (295(2)):435-443 doi:10.1074/jbc.AC119.009890.

    PMID: 31767681
  21. 21

    Microtubule-dependent and independent roles of spastin in lipid droplet dispersion and biogenesis.

    Tadepalle N, Robers L, Veronese M, et al.

    Life science alliance 2020; (3(6)) doi:10.26508/lsa.202000715.

    PMID: 32321733
  22. 22

    Inhibition of ER stress improves progressive motor deficits in a REEP1-null mouse model of hereditary spastic paraplegia.

    Wang B, Yu Y, Wei L, Zhang Y

    Biology open 2020; (9(9)) doi:10.1242/bio.054296.

    PMID: 32878877
  23. 23

    SEIPIN: A Key Factor for Nuclear Lipid Droplet Generation and Lipid Homeostasis.

    Jin Y, Tan Y, Zhao P, Ren Z

    International journal of molecular sciences 2020; (21(21)) doi:10.3390/ijms21218208.

    PMID: 33147895
  24. 24

    N88S seipin-related seipinopathy is a lipidopathy associated with loss of iron homeostasis.

    Ribeiro MO, Oliveira M, Nogueira V, et al.

    Cell communication and signaling : CCS 2025; (23(1)):10 doi:10.1186/s12964-024-02007-9.

    PMID: 39773523
  25. 25

    Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.

    Zhou H, Lei X, Yan Y, et al.

    JCI insight 2019; (5()).

    PMID: 31185001
  26. 26

    Ascending Axonal Degeneration of the Corticospinal Tract in Pure Hereditary Spastic Paraplegia: A Cross-Sectional DTI Study.

    List J, Kohl Z, Winkler J, et al.

    Brain sciences 2019; (9(10)) doi:10.3390/brainsci9100268.

    PMID: 31601037

This page explains the genetics and biology of AD-HSP for educational purposes only. Always consult a genetic counselor or neurologist regarding your specific genetic test results and family risk.

Get notified when new evidence is published on Autosomal dominant complex spastic paraplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.